Repligen AI Stock Analysis
Want to see RGEN full AI Analyst Report?
Repligen (RGEN) AI Stock Analysis
Repligen
(NASDAQ:RGEN)
RGEN scores mid-range primarily due to strong cash flow and a solid balance sheet supporting flexibility, reinforced by upbeat guidance and positive management sentiment pointing to accelerating growth. These positives are tempered by currently weak GAAP profitability (negative TTM net income), weak-to-neutral near-term technical momentum, and an unfavorable valuation signal from the deeply negative P/E with no dividend yield provided.
Repligen (RGEN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.37B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.19M
- Price to Earnings (P/E)
- -770.4
- Beta (1Y)
- 1.38
- Revenue Growth
- 13.80%
- EPS Growth
- -811.00%
- Country
- US
- Employees
- 2,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Repligen Business Overview & Revenue Model
Company Description
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe,...
How the Company Makes Money
Repligen makes money primarily by selling bioprocessing products to biopharmaceutical and life sciences customers that manufacture biologic drugs. Its revenue model is largely product-based and is typically driven by: (1) recurring sales of consumabl...
Repligen Earnings Call Summary
The call was strongly positive overall. Repligen reported record revenue, double-digit organic growth, operating margin expansion, higher full-year guidance, strong demand in chromatography, proteins, analytics, China, services, and capital equipment orders, and encouraging early progress integrating BioLife. The company acknowledged meaningful challenges, including an 11% filtration decline, delayed equipment revenue conversion, a 30-basis-point gross margin decline, customer decision delays, and on-shoring projects running 9 to 12 months behind expectations, but management expressed confidence in the 2027 outlook and continued market-share and growth opportunities.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Repligen guides to $844 million to $852 million of revenue, or $848 million at the midpoint, representing 14.5% to 15.5% reported growth and 12% to 13% organic growth, including approximately $24 million from BioLife, an approximately 1-point headwind from the sale of PolyMem operations, and neutral foreign currency; franchise guidance is filtration flat to slightly down, chromatography greater than 30%, proteins mid-teens, and analytics more than 30% growth. The company expects 110- to 160-basis-points of gross margin expansion, adjusted operating income of $135 to $139 million, adjusted operating margin of 16% to 16.3%, adjusted other income of $18 million, an adjusted tax rate of approximately 22%, adjusted fully diluted earnings per share of $2.05 to $2.09, and CapEx of approximately 3% to 4% of 2026 revenue; fourth quarter organic growth is expected to be in the range of the updated full year outlook, fourth quarter gross margin within the full year guidance, and operating expenses up low-double-digits million sequentially. For 2027, assuming the market is growing high-single-digits and absent a material change in foreign exchange rates, reported top-line growth is positioned at least 25%, revenue is expected to exceed $1 billion, and BioLife is expected to deliver at least $0.05 of Year 1 accretion, while the company continues to target outpacing market growth by more than 500 basis points; the 2027 framework is not a formal guidance.
Repligen Financial Statement Overview
Summary
Financials are supported by a solid balance sheet (72) with moderate leverage and strong cash generation (74) with healthy free cash flow, but overall performance is held back by mixed earnings quality: revenue has stabilized and EBITDA remains positive, yet TTM net income is negative and margins are below 2021–2022 peak levels (income statement score 58).
Income Statement
58NeutralBalance Sheet
72PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 805.61M | 738.26M | 634.44M | 632.36M | 801.54M | 670.53M |
| Gross Profit | 411.27M | 347.62M | 274.64M | 278.44M | 455.71M | 391.25M |
| EBITDA | 125.87M | 182.51M | 80.26M | 145.32M | 277.31M | 203.27M |
| Net Income | -11.80M | 48.89M | -25.51M | 35.60M | 185.96M | 128.29M |
Balance Sheet | ||||||
| Total Assets | 2.93B | 2.95B | 2.83B | 2.83B | 2.53B | 2.36B |
| Cash, Cash Equivalents and Short-Term Investments | 862.98M | 767.63M | 757.36M | 751.32M | 623.76M | 603.81M |
| Total Debt | 692.24M | 689.95M | 686.25M | 711.80M | 422.96M | 366.05M |
| Total Liabilities | 834.67M | 843.57M | 856.95M | 866.34M | 620.90M | 608.29M |
| Stockholders Equity | 2.09B | 2.11B | 1.97B | 1.96B | 1.91B | 1.75B |
Cash Flow | ||||||
| Free Cash Flow | 106.22M | 93.90M | 142.49M | 74.93M | 38.74M | 51.93M |
| Operating Cash Flow | 129.86M | 117.42M | 175.39M | 113.92M | 172.08M | 119.02M |
| Investing Cash Flow | -150.83M | -298.47M | -86.38M | -123.28M | -233.24M | -221.17M |
| Financing Cash Flow | 3.06M | -15.21M | -82.90M | 248.96M | -13.34M | 961.00K |
Repligen Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Negative. The current price of 162.18 is below the 20-day moving average (MA) of 174.90, below the 50-day MA of 176.92, and above the 200-day MA of 145.39, indicating a neutral trend. The MACD of -3.29 indicates Positive momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 8.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RGEN.
Repligen Risk Analysis
Repligen disclosed 18 risk factors in its most recent earnings report. Repligen reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksRepligen Peers Comparison
Overall Rating
WST78Outperform
AVTR66Neutral
RGEN63Neutral
STVN62Neutral
SOLV50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $28.85B | 46.15 | 21.08% | 0.22% | 12.60% | 32.05% | |
| 66Neutral | $10.29B | 30.22 | 5.96% | ― | 0.92% | ― | |
| 63Neutral | $10.37B | -770.41 | -0.56% | ― | 13.80% | -811.00% | |
| 62Neutral | $4.16B | 27.79 | 9.07% | 0.41% | 11.99% | 4.96% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $14.61B | 97.47 | 3.18% | ― | -3.09% | -89.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RGEN | Repligen | 162.18 | 7.10 | 4.58% | |
| WST | West Pharmaceutical Services, Inc. | 414.12 | 156.98 | 61.05% | |
| AVTR | Avantor | 15.18 | 4.17 | 37.87% | |
| STVN | Stevanato Group Spa | 15.25 | -6.01 | -28.28% | |
| SOLV | Solventum Corporation | 86.06 | 8.75 | 11.32% |
Repligen Corporate Events
Repligen Issues $1 Billion Convertible Notes, Restructures Debt
PositiveOn November 6, 2026, Repligen issued $1.0 billion of 0.25% convertible senior notes due 2031 through previously announced exchange and subscription transactions. About $541.4 million of the new notes replaced $456.8 million of 1.00% notes due 2028, w...
Repligen Announces New Convertible Notes and Capital Restructuring
PositiveOn October 30, 2026, Repligen announced privately negotiated exchange and subscription agreements through which it will issue $1.0 billion of 0.25% Convertible Senior Notes due 2031, partly swapping $456.8 million of its 1.00% Convertible Senior Note...
Repligen Completes BioLife Acquisition to Expand Cell Therapies
PositiveRepligen has completed its acquisition of BioLife Solutions, a leading developer and supplier of cell processing tools and biopreservation media for the cell and gene therapy market, in a transaction that closed on October 6, 2026. The deal broadens...
Repligen announces long-serving director Karen Dawes’ retirement
NeutralOn September 10, 2026, Repligen Corporation announced that Karen A. Dawes will retire from its Board of Directors on September 30, 2026, after more than two decades of service. Her tenure spanned a period of significant transformation for the company...
Repligen clears antitrust hurdle in BioLife Solutions acquisition
PositiveOn July 21, 2026, Repligen entered into a merger agreement to acquire BioLife Solutions, Inc., with BioLife stockholders to receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife common stock. The transaction is s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
